Latest Regulatory News

Latitude Group Holdings is considering launching a new Capital Notes 2 offer, potentially allowing existing CN1 holders to reinvest. The offer will require applications through appointed Syndicate Brokers under updated regulatory rules.

ABx Group has announced a breakthrough with its second mixed rare earth carbonate sample from Tasmania’s Deep Leads deposit, boasting higher heavy rare earth content and fewer impurities. This advancement enhances project flexibility and strengthens ABx’s position in the competitive rare earths market.

NH3 Clean Energy has locked in a crucial 15-year water supply agreement with the Water Corporation of WA for its flagship WAH2 clean ammonia project, marking a key step towards its final investment decision.

Perpetual Limited has agreed to sell its Wealth Management business to Bain Capital for an upfront $500 million, marking a strategic shift towards asset management and corporate trustee services.

Strike Energy reports a significant 35% increase in the Benchmark Reserve Capacity Price for 2028/29, alongside strong construction progress at its South Erregulla Power Project, signalling robust prospects for WA’s energy transition.

Dataworks Group Limited reveals ongoing strategic review with several parties engaged, highlighting the value of its self-exclusion technology and regulatory ties. While discussions remain preliminary, the company signals potential for significant strategic moves ahead.

Dimerix Limited is set to conduct a blinded statistical review of its pivotal Phase 3 ACTION3 study in March 2026, aiming to confirm the trial remains powered to demonstrate the primary endpoint of proteinuria reduction in FSGS patients.

Syrah Resources has secured an extension to the cure date for an alleged default under its Tesla offtake agreement, pushing the deadline from March to June 2026 as both parties work to resolve outstanding issues.

Neurizon Therapeutics announces the resignation of CEO Dr Michael Thurn, with Executive Chair Sergio Duchini stepping in temporarily as the company embarks on a global hunt for new leadership.

Telix Pharmaceuticals has resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara®), aiming to advance a novel PET imaging agent for glioma diagnosis. The resubmission addresses prior regulatory concerns with additional data, reinforcing hopes for expedited approval.

Bio-Gene has signed a term sheet with Sumitomo Corporation and Nakashima Trading to introduce its 100% natural insecticide Qcide® to Japan’s $1 billion household pest market, aiming for a late 2026 launch.

EMVision Medical Devices has secured a $3.8 million R&D tax rebate and gained approval to claim rebates on overseas expenditures, strengthening its financial footing as it advances clinical trials for its neurodiagnostic device.